What Is Spravato?
SPRAVATO is a prescription Esketamine nasal spray used along with an antidepressant taken by mouth to treat adults with Treatment-resistant depression.
It is not known if SPRAVATO is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed if the improvement is experienced after the first dose of SPRAVATO.
To learn more about these and other risks, visit www.SPRAVATO.com
How Does Spravato Work?
Spravato is the only N-methyl-D-aspartate (NMDA) receptor antagonist approved in conjunction with an oral antidepressant for adult patients with treatment-resistant depression (TRD).
Eskatamine is molecularly different than ketamine, where the S-ketamine is separated out, called an S-enantiomer. Esketamine, or Spravato, is known to bind to certain brain receptors that play a part in depression.
Spravato is commonly prescribed as a supplemental medication in addition to oral antidepressants, potentially boosting the effect of your current prescribed antidepressant.
How is Spravato Administered?
Spravato must be self-administered through a nasal spray device onsite at Colorado Recovery Solutions. You will be monitored by a licensed medical professional for at least two hours. Please note, Spravato is never prescribed for home use.
- Spravato is taken twice a week for the first four weeks
- After the first four weeks, Spravato is taken once a week for a month
- After this, Spravato is usually taken either once a week or once every two weeks
Colorado Recovery Solutions is the only Spravato-REMS certified, psychiatric physician-owned clinic in the greater Colorado Springs area. As a part of the FDA-mandated Spravato-REMS program, our psychiatrist will discuss the risks of sedation, dissociation, abuse and misuse with you before starting SPRAVATO. Your healthcare provider can refer you to our specialty clinic specifically for SPRAVATO consultation and treatments. We are happy to collaborate with your already established healthcare providers while you are enrolled in the SPRAVATO treatment program. For more information, please visit https://www.spravatorems.com/patients.html.
Spravato payment options
Spravato is covered by most insurances. If you are interested in Spravato and are not sure your insurance covers Spravato or don’t have insurance, give us a call at (719) 622-6522
Colorado Recovery Solutions is an FDA-mandated, Spravato-REMS certified treatment location and is currently accepting referrals for this specialty treatment. Colorado Recovery Solutions values a collaborative approach to patient care. We work in tandem with outside psychiatric prescribers to provide SPRAVATO to your patients without interrupting established patient-provider relationships.
Patient referrals for SPRAVATO can be completed through our secure consultation form at the bottom of this page or by:
Phone: (729) 622-6522
Fax: (719) 622-6520
Most insurances, including Medicare, cover Spravato for treatment resistant depression (TRD) and TRD with acute suicidal ideations(ASI) . You can call your insurance directly or we can help verify your benefits for Spravato if you send a picture of the front and back of your insurance card to email@example.com.
- Common side effects of Spravato are: Dissociation, Dizziness, Nausea, Sedation, Vertigo, Numbness, Anxiety, Lethargy, Increased blood pressure.
Spravato nasal spray is indicated, in conjunction with an oral anti-depressant for the treatment of:
● Treatment-resistant depression in adults.
● Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. Limitations of Spravato include:
● The effectiveness of Spravato in preventing suicide or in reducing suicidal ideation or behvaior has not been demonstrated. Use of Sparvato does not preclude the need for hospitalization if clinically warranted , even if patients experience improvement after an initial dose of Spravato.
● Spravato is not approved as an anesthetic agent. The safety and effectiveness of Spravato as an anesthetic agent have not been established.
- The induction phase includes administering the nasal spray in-office twice a week, for 1-4 weeks.
- Based on a patient’s response, additional weeks of treatment may be needed.
- A driver is REQUIRED to be present during every administration of Spravato
READY TO BEGIN YOUR JOURNEY TO BETTER HEALTH?
Contact us and we’ll get back to you to schedule a consultation.